Scarica l'app Stockscreener
2.08
0.95%
-0.02
Dopo l'orario di chiusura:
2.13
0.05
+2.40%
OncoCyte Corporation Borsa (OCX) Ultime notizie
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock - Investing.com India
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock By Investing.com - Investing.com Australia
OncoCyte (STU:7OC0) PS Ratio : 47.04 (As of Jan. 15, 2025) - GuruFocus.com
OncoCyte Co. (NASDAQ:OCX) Shares Bought by Geode Capital Management LLC - Defense World
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
OncoCyte Corporation (NASDAQ: OCX) Enters Amendment to Lease Agreement with Induce Biologics USA, Inc. and Cushing Ventures, LLCOn January 2, 2025, Oncocyte Corporation announced in a Form 8-K filing that it has entered into an Amendment to a - Defense World
Oncocyte Corp amends lease agreement, sets expiration date By Investing.com - Investing.com Nigeria
Oncocyte Corp amends lease agreement, sets expiration date - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - Markets Insider
Oncocyte names Dr. Paul Billings as Consulting CMO - Investing.com India
Oncocyte Taps Harvard-Trained Diagnostics Veteran Dr. Paul Billings as Chief Medical Officer - StockTitan
Medicare expands coverage for kidney transplant test By Investing.com - Investing.com Australia
OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com - Defense World
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - The Manila Times
Oncocyte's VitaGraft Kidney Test Gains Expanded Medicare Coverage for Early Rejection Detection - StockTitan
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World
Oncocyte corp investor Patrick Smith buys $192,166 in stock By Investing.com - Investing.com Nigeria
OncoCyte stock hits 52-week low at $1.97 amid market challenges - Investing.com Nigeria
Oncocyte corp director Arno Andrew buys $26,350 in shares - Investing.com India
StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX) - Defense World
OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com - Defense World
Oncocyte to Participate in 'J.P. Morgan Week” and Host Investor Meetings - The Manila Times
Oncocyte corp CFO James Andrea acquires $45,800 in stock - Investing.com India
Oncocyte corp CFO James Andrea acquires $45,800 in stock By Investing.com - Investing.com Canada
Oncocyte Corp to Meet Investors at J.P. Morgan Healthcare Conference 2025 - StockTitan
OCXOncocyte Corporation Latest Stock News & Market Updates - StockTitan
OncoCyte stock hits 52-week low at $1.98 amid market challenges - Investing.com Nigeria
OncoCyte stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Oncocyte study shows potential for non-invasive brain tumor diagnosis By Investing.com - Investing.com Nigeria
Oncocyte study shows potential for non-invasive brain tumor diagnosis - Investing.com
OncoCyte announces publication of DetermaCNI assay data - TipRanks
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study - The Manila Times
Oncocyte's Brain Cancer Liquid Biopsy Test Shows Breakthrough 83% Detection Rate in Clinical Study - StockTitan
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms - The Manila Times
OncoCyte (LTS:0KCC) Shares Outstanding (EOP) : 13.37 Mil (As of Sep. 2024) - GuruFocus.com
OncoCyte announces VitaGraft data published in journal - TipRanks
Oncocyte's VitaGraft Kidney Test Detects Transplant Rejection 11 Months Earlier in Clinical Study - StockTitan
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
OCX (OncoCyte) EPS without NRI : $-2.33 (TTM As of Sep. 2024) - GuruFocus.com
OncoCyte stock plunges to 52-week low at $2.18 amid market challenges By Investing.com - Investing.com South Africa
OncoCyte stock plunges to 52-week low at $2.18 amid market challenges - Investing.com Nigeria
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):